Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974767 | 1.00 | PLAU (0.47) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL17974765 | 1.00 | PLAU (0.47) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL11742887 | 0.89 | TSHR (0.41) | PLAUMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL5500714 | 0.86 | IDO1 (0.38) | PLAUCA1CA2ANPEP | |
| SCHEMBL5657816 | 0.81 | CYP2A6 (0.44) | CYP19A1MAOAMAOB | |
| SCHEMBL30150914 | 0.71 | IDO1 (0.44) | CA1CA2 | |
| SCHEMBL2115194 | 0.71 | IDO1 (0.44) | CA1CA2 | |
| SCHEMBL27842818 | 0.70 | — | — | |
| SCHEMBL8557409 | 0.69 | NISCH (0.40) | HTR1ATP53MAOB | |
| SCHEMBL277274 | 0.69 | PLAU (0.56) | PLAUMTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | BIAL-PORTELA & CA., S.A. (PT) | 2016-08-04 | — | — | US | disclosed |
| WO-2012175654-A1 | TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE-DAME DE LA PAIX (BE) | 2012-12-27 | — | — | WO | disclosed |
| US-7671079-B2 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-7288561-B2 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-30 | — | — | US | disclosed |
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| CN-1212682-A | Aminotetralin derivatives and composition and method of use thereof | ZENECA LTD (GB) | 1999-03-31 | — | — | CN | disclosed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | disclosed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | PLAU 4268/4885MTNR1A 46/4885MTNR1B 55/4885 |
| US-20160221981-A1 | Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein | DBH, COMT, ADRB3 | PLAU 1878/4885MTNR1A 53/4885MTNR1B 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.